MedPath

Transitional Care Model Evaluation 2020

Not Applicable
Active, not recruiting
Conditions
CHF - Congestive Heart Failure
Pneumonia
COPD
Registration Number
NCT04212962
Lead Sponsor
Mathematica Policy Research, Inc.
Brief Summary

The study is a randomized controlled trial to estimate the effects of the transitional care model (TCM) on hospital admissions and patients' experience during the year following the patient's qualifying discharge. The University of Pennsylvania, where TCM was developed, will be the coordinating center for the implementation. The study will be conducted in three large health systems spread throughout the U.S., drawing patients from seven hospitals in those systems. Eligible patients are older adults (age 65 and older) admitted to a participating hospital with symptoms of heart failure (HF), chronic obstructive pulmonary disease (COPD), or pneumonia (PNA). The evaluation will be conducted by Mathematica.

Detailed Description

The Transitional Care Model (TCM) is an advanced practice registered nurse (APRN) led, team-based, care management strategy designed to improve the care and outcomes of high-risk older adults transitioning from hospital to home. Eligible patients who agree to participate in the study will be randomly assigned to either the intervention group, which receives the TCM intervention, or the control group, which receives usual care (standard hospital discharge planning and post-hospital follow up services). The target sample size for the study is close to 1000, evenly divided into intervention and control groups, with 250 to 270 patients derived from each of UCSF and Trinity health systems, and another 450 recruited from the two VHA hospitals combined. Data will be collected at intake, prior to randomization, by enrollment coordinators at each of the participating hospitals. Followup data will be collected in a survey of patients conducted 90 days after discharge, and from claims data obtained from Medicare, Medicare Advantage plans, and the VHA.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
962
Inclusion Criteria
  • Age 65 years and older
  • Admitted from home with Pneumonia OR with a history of HF or COPD with symptoms of HF or COPD exacerbation or whose symptoms suggest a new HF or COPD diagnosis
  • English and non-English speaking, able to respond to questions
  • Reachable by telephone after discharge
  • Resides within the geographic service area
  • Consent to participation
Exclusion Criteria
  • Enrolled in Medicare's Hospice or End-Stage Renal Disease programs
  • Presence of active and untreated psychiatric conditions (ICD10: F10-F29)
  • Long-term care resident
  • Undergoing active cancer treatment
  • Currently enrolled in another RCT

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Number of hospital admissions12 months

number of times admitted to the hospital during 12 months after initial discharge

Costs12 months

Costs of medical care paid for by Medicare, Medicare Advantage plan, or Veterans Health Administration

Secondary Outcome Measures
NameTimeMethod
30-day readmission30 days

whether readmitted to a hospital during the 30 days after initial discharge

Patient-Reported Outcomes Measurement Information System Physical Functioning (SF10a)90 days after initial discharge

functional status, range 10-50, high score is good

Mortality12 months after initial discharge

whether died after initial discharge

Edmonton Symptom Assessment Scale90 days after initial discharge

measures post-hospital symptoms, range 0-100, high score is bad

Patient Health Questionnaire for Depression and Anxiety (PHQ-4)90 days after initial discharge

index of depression and anxiety, range 0-12, high score is bad

emergency department visits12 months

number of times treated in an emergency department after initial discharge

Trial Locations

Locations (1)

Mathematica Policy Research

🇺🇸

Princeton, New Jersey, United States

Mathematica Policy Research
🇺🇸Princeton, New Jersey, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.